Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck

Cancer Research

Volumn 65, Issue 23, 2005, Pages 11146-11155

  Albers, Andreas ^a   Abe, Koji ^a   Hunt, Jennifer ^a   Wang, Jun ^a   Lopez Albaitero, Andres ^a   Schaefer, Carsten ^a   Gooding, William ^a   Whiteside, Theresa L ^a   Ferrone, Soldano ^b   DeLeo, Albert ^a   Ferris, Robert L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR7; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PROTEIN E7; TETRAMER; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; DOWN REGULATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STAINING; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HEAD AND NECK NEOPLASMS; HLA-A ANTIGENS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; MALE; MICE; MICE, TRANSGENIC; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 28244456274     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0772     Document Type: Article

References (33)

1. Gillison ML, Shah KV. Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol 2001;13:183-8.
2. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
3. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2342-50.
4. Youde SJ, Dunbar PR, Evans EM, et al. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte- recognizing endogenous human papillomavirus antigens. Cancer Res 2000; 60:365-71.
5. - T cells have signalling defects in patients with squamous cell carcinoma of the head and neck. Br J Cancer 2003;88:223-30.
6. + T cells through the combination of MHC class I tetramer and intracellular staining. J Immunol Methods 2002;268:9-19.
7. Ferris RL, Martinez I, Sirianni N, et al. Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis. Eur J Cancer 2005;41:807-15.
8. Ragin CC, Reshmi SC, Gollin SM. Mapping and analysis of HPV16 integration sites in a head and neck cancer cell line. Int J Cancer 2004;110:701-9.
9. Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 2002;94: 2199-210.
10. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cell 1989;89:209-14.
11. Ericsson C, Seregard S, Bartolazzi A, et al. Association of HLA class I, class II. Antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci 2001;42: 2153-6.
12. Ogino T, Wang X, Ferrone S. Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J Immunol Methods 2003;278:33-44.
13. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 2003;62:385-93.
14. Parham P, Barnstable CJ, Bodmer VW. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A B,C, antigens. J Immunol 1979;123:342-9.
15. Parham P, Bodmer WF. Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2. Nature 1978;276:397-9.
16. Salter RD, Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J 1986;5:943-9.
17. Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985;21:235-46.
18. + T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002;8:379-85.
19. + T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res 2002; 62:3521-9.
20. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
21. + T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:6929-37.
22. Ferris RL, JLH, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res. In press 2005.
23. Kreimer AR, Alberg AJ, Daniel R, et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 2004;189:686-98.
24. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-12.
25. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
26. + T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003;171:2251-61.
27. Whiteside TL, Odoux C. Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 2004;53:240-8.
28. + T cell cross-priming via transfer of proteasome substrates. Science 2004;304:1318-21.
29. Vambutas A, DeVoti J, Pinn W, Steinberg BM, Bonagura VR. Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. Clin Immunol 2001; 101:94-9.
30. Sallusto F, Kremmer E, Palermo B, et al. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol 1999;29:2037-45.
31. De Paola F, Ridolfi R, Riccobon A, et al. Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2. Br J Cancer 2003;88:320-6.
32. Brady CS, Bartholomew JS, Burt DJ, et al. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 2000;55:401-11.
33. Evans M, Borysiewicz LK, Evans AS, et al. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 2001;167:5420-8.